Efficient molecular subtype classification of high-grade serous ovarian cancer

Journal of Pathology

Volumn 236, Issue 3, 2015, Pages 272-277

  Leong, Huei San ^a   Galletta, Laura ^a   Etemadmoghadam, Dariush ^a,b,c   George, Joshy ^a,d,e,f   Köbel, Martin ^g   Ramus, Susan J ^h   Bowtell, David ^a,c,i  

^a PETER MACCALLUM CANCER CENTRE   (Australia)

^b UNIVERSITY OF MELBOURNE   (Australia)

^c UNIVERSITY OF MELBOURNE   (Australia)

^d JACKSON LABORATORY   (United States)

^e QIMR BERGHOFER MEDICAL RESEARCH INSTITUTE   (Australia)

^f UNIVERSITY OF SYDNEY   (Australia)

^g UNIVERSITY OF CALGARY   (Canada)

^h UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

ⁱ HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

classification; Fluidigm; Illumina targeted RNA expression; molecular subtypes; Nanostring; serous ovarian cancer; TaqMan low density arrays

Indexed keywords

FRESH FROZEN PLASMA; OLIGONUCLEOTIDE; RNA; PARAFFIN;

ARTICLE; CANCER CLASSIFICATION; CANCER GENETICS; CANCER SURVIVAL; DIFFERENTIATED HIGH GRADE SEROUS OVARIAN CANCER; FEMALE; FLUIDIGM; GENE CONTROL; GENE EXPRESSION PROFILING; HIGH GRADE SEROUS OVARIAN CANCER; HUMAN; ILLUMINA TARGETED RNA; IMMUNOREACTIVE HIGH GRADE SEROUS OVARIAN CANCER; IMMUNOREACTIVITY; MAJOR CLINICAL STUDY; MESENCHYMAL HIGH GRADE SEROUS OVARIAN CANCER; MICROARRAY ANALYSIS; MOLECULAR PATHOLOGY; NANOSTRING GENE EXPRESSION PLATFORM; NEXT GENERATION SEQUENCING; OVARY CANCER; OVERALL SURVIVAL; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROLIFERATIVE HIGH GRADE SEROUS OVARIAN CANCER; RNA SEQUENCE; TAQMAN BASED LOW DENSITY ARRAY; TUMOR MICROENVIRONMENT; CLASSIFICATION; CYSTADENOCARCINOMA; DNA MICROARRAY; FROZEN SECTION; GENE EXPRESSION REGULATION; GENETICS; HIGH THROUGHPUT SEQUENCING; NEOPLASM; OVARY TUMOR; REPRODUCIBILITY; SEQUENCE ANALYSIS;

CYSTADENOCARCINOMA, SEROUS; FEMALE; FROZEN SECTIONS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION, NEOPLASTIC; HIGH-THROUGHPUT NUCLEOTIDE SEQUENCING; HUMANS; NEOPLASMS, GLANDULAR AND EPITHELIAL; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; OVARIAN NEOPLASMS; PARAFFIN EMBEDDING; REPRODUCIBILITY OF RESULTS; SEQUENCE ANALYSIS, RNA;

EID: 84930477824     PISSN: 00223417     EISSN: 10969896     Source Type: Journal    
DOI: 10.1002/path.4536     Document Type: Article

References (24)

1. Kobel M, Bak J, Bertelsen BI, et al., Ovarian carcinoma histotype determination is highly reproducible, and is improved through the use of immunohistochemistry. Histopathology 2014; 64: 1004-1013.
2. Gates MA, Rosner BA, Hecht JL, et al., Risk factors for epithelial ovarian cancer by histologic subtype. Am J Epidemiol 2010; 171: 45-53.
3. Goode EL, Chenevix-Trench G, Song H, et al., A genome-wide association study identifies susceptibility loci for ovarian cancer at 2q31 and 8q24. Nature Genet 2010; 42: 874-879.
4. Wiegand KC, Shah SP, Al-Agha OM, et al., ARID1A mutations in endometriosis-associated ovarian carcinomas. N Engl J Med 2010; 363: 1532-1543.
5. Sugiyama T, Kamura T, Kigawa J, et al., Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor prognosis and resistance to platinum-based chemotherapy. Cancer 2000; 88: 2584-2589.
6. Vaughan S, Coward JI, Bast RC Jr, et al. Rethinking ovarian cancer: recommendations for improving outcomes. Nature Rev Cancer 2011; 11: 719-725.
7. Tothill RW, Tinker AV, George J, et al., Novel molecular subtypes of serous and endometrioid ovarian cancer linked to clinical outcome. Clin Cancer Res 2008; 14: 5198-5208.
8. The Cancer Genome Atlas (TCGA) Network. Integrated genomic analyses of ovarian carcinoma. Nature 2011; 474: 609-615.
9. Tan TZ, Miow QH, Huang RY, et al., Functional genomics identifies five distinct molecular subtypes with clinical relevance and pathways for growth control in epithelial ovarian cancer. EMBO Mol Med 2013; 5: 983-998.
10. Zhang L, Conejo-Garcia JR, Katsaros D, et al., Intratumoral T cells, recurrence, and survival in epithelial ovarian cancer. N Engl J Med 2003; 348: 203-213.
11. Helland A, Anglesio MS, George J, et al., Deregulation of MYCN, LIN28B and LET7 in a molecular subtype of aggressive high-grade serous ovarian cancers. PLoS One 2011; 6: e18064.
12. Abruzzo LV, Lee KY, Fuller A, et al., Validation of oligonucleotide microarray data using microfluidic low-density arrays: a new statistical method to normalize real-time RT-PCR data. Biotechniques 2005; 38: 785-792.
13. Spurgeon SL, Jones RC, Ramakrishnan R,. High throughput gene expression measurement with real time PCR in a microfluidic dynamic array. PLoS One 2008; 3: e1662.
14. Geiss GK, Bumgarner RE, Birditt B, et al., Direct multiplexed measurement of gene expression with color-coded probe pairs. Nature Biotechnol 2008; 26: 317-325.
15. Sorlie T, Perou CM, Tibshirani R, et al., Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 2001; 98: 10869-10874.
16. Mullins M, Perreard L, Quackenbush JF, et al., Agreement in breast cancer classification between microarray and quantitative reverse transcription PCR from fresh-frozen and formalin-fixed, paraffin-embedded tissues. Clin Chem 2007; 53: 1273-1279.
17. Northcott PA, Shih DJ, Remke M, et al., Rapid, reliable, and reproducible molecular sub-grouping of clinical medulloblastoma samples. Acta Neuropathol 2012; 123: 615-626.
18. Winterhoff B, Kommoss S, Oberg AL, et al., Bevacizumab and improvement of progression-free survival (PFS) for patients with the mesenchymal molecular subtype of ovarian cancer. J Clin Oncol 2014; 32: 5s (Suppl; Abstr 5509).
19. Gourley C, McCavigan A, Perren T, et al., Molecular subgroup of high-grade serous ovarian cancer (HGSOC) as a predictor of outcome following bevacizumab. J Clin Oncol 2014; 32: 5s (Suppl; Abstr 5502).
20. Verhaak RG, Tamayo P, Yang JY, et al., Prognostically relevant gene signatures of high-grade serous ovarian carcinoma. J Clin Invest 2013; 123: 517-525.
21. Etemadmoghadam D, deFazio A, Beroukhim R, et al., Integrated genome-wide DNA copy number and expression analysis identifies distinct mechanisms of primary chemoresistance in ovarian carcinomas. Clin Cancer Res 2009; 15: 1417-1427.
22. Smyth GK,. Limma: linear models for microarray data. In Bioinformatics and Computational Biology Solutions Using R and Bioconductor, Gentleman R, Carey V, Huber W, et al (eds). Springer: New York, 2005; 397-420.
23. Law CW, Chen Y, Shi W, et al., voom: Precision weights unlock linear model analysis tools for RNA-seq read counts. Genome Biol 2014; 15: R29.
24. Dudoit S, Fridlyand J, Speed TP,. Comparison of discrimination methods for the classification of tumors using gene expression data. J Am Stat Assoc 2002; 97: 77-87.